Assessment of chimerism by next generation sequencing : A comparison to STR/qPCR methods
Copyright © 2024 American Society for Histocompatibility and Immunogenetics. All rights reserved..
Chimerism analysis is used to evaluate patients after allogeneic hematopoietic stem cell transplant (allo-HSCT) for engraftment and minimal measurable residual disease (MRD) monitoring. A combination of short-tandem repeat (STR) and quantitative polymerase chain reaction (qPCR) was required to achieve both sensitivity and accuracy in the patients with various chimerism statuses. In this study, an insertion/deletion-based multiplex chimerism assay by next generation sequencing (NGS) was evaluated using 5 simulated unrelated donor-recipient combinations from 10 volunteers. Median number of informative markers detected was 8 (range = 5 - 11). The limit of quantitation (LoQ) was determined to be 0.1 % recipient. Assay sample number/batch was 10-20 and total assay time was 19-31 h (manual labor = 2.1 h). Additionally, 50 peripheral blood samples from 5 allo-HSCT recipients (related: N = 4; unrelated: N = 1) were tested by NGS and STR/qPCR. Median number of informative markers detected was 7 (range = 4 - 12). Results from both assays demonstrated a strong correlation (Y = 0.9875X + 0.333; R2 = 0.9852), no significant assay bias (difference mean - 0.08), and 100 % concordant detection of percent recipient increase ≥ 0.1 % (indicator of increased relapse risk). NGS-based chimerism assay can support all allo-HSCT for engraftment and MRD monitoring and simplify clinical laboratory workflow compared to STR/qPCR.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Human immunology - (2024) vom: 28. März, Seite 110794 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Brow, Darren [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Allogenic hematopoietic stem cell transplant |
|---|
| Anmerkungen: |
Date Revised 29.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.humimm.2024.110794 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370429095 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370429095 | ||
| 003 | DE-627 | ||
| 005 | 20240331002548.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240331s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.humimm.2024.110794 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1357.xml |
| 035 | |a (DE-627)NLM370429095 | ||
| 035 | |a (NLM)38553384 | ||
| 035 | |a (PII)S0198-8859(24)00054-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Brow, Darren |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Assessment of chimerism by next generation sequencing |b A comparison to STR/qPCR methods |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 29.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024 American Society for Histocompatibility and Immunogenetics. All rights reserved. | ||
| 520 | |a Chimerism analysis is used to evaluate patients after allogeneic hematopoietic stem cell transplant (allo-HSCT) for engraftment and minimal measurable residual disease (MRD) monitoring. A combination of short-tandem repeat (STR) and quantitative polymerase chain reaction (qPCR) was required to achieve both sensitivity and accuracy in the patients with various chimerism statuses. In this study, an insertion/deletion-based multiplex chimerism assay by next generation sequencing (NGS) was evaluated using 5 simulated unrelated donor-recipient combinations from 10 volunteers. Median number of informative markers detected was 8 (range = 5 - 11). The limit of quantitation (LoQ) was determined to be 0.1 % recipient. Assay sample number/batch was 10-20 and total assay time was 19-31 h (manual labor = 2.1 h). Additionally, 50 peripheral blood samples from 5 allo-HSCT recipients (related: N = 4; unrelated: N = 1) were tested by NGS and STR/qPCR. Median number of informative markers detected was 7 (range = 4 - 12). Results from both assays demonstrated a strong correlation (Y = 0.9875X + 0.333; R2 = 0.9852), no significant assay bias (difference mean - 0.08), and 100 % concordant detection of percent recipient increase ≥ 0.1 % (indicator of increased relapse risk). NGS-based chimerism assay can support all allo-HSCT for engraftment and MRD monitoring and simplify clinical laboratory workflow compared to STR/qPCR | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Allogenic hematopoietic stem cell transplant | |
| 650 | 4 | |a Chimerism testing | |
| 650 | 4 | |a Measurable residual disease | |
| 650 | 4 | |a Next generation sequencing | |
| 650 | 4 | |a Relapse | |
| 700 | 1 | |a Shike, Hiroko |e verfasserin |4 aut | |
| 700 | 1 | |a Kendrick, Jasmine |e verfasserin |4 aut | |
| 700 | 1 | |a Pettersson, Linnea |e verfasserin |4 aut | |
| 700 | 1 | |a Mineishi, Shin |e verfasserin |4 aut | |
| 700 | 1 | |a Claxton, David F |e verfasserin |4 aut | |
| 700 | 1 | |a Wirk, Baldeep |e verfasserin |4 aut | |
| 700 | 1 | |a Cioccio, Joseph |e verfasserin |4 aut | |
| 700 | 1 | |a Greiner, Robert J |e verfasserin |4 aut | |
| 700 | 1 | |a Viswanatha, David |e verfasserin |4 aut | |
| 700 | 1 | |a Kharfan-Dabaja, Mohamed A |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Zhuo |e verfasserin |4 aut | |
| 700 | 1 | |a Tyler, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Elrefaei, Mohamed |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Human immunology |d 1991 |g (2024) vom: 28. März, Seite 110794 |w (DE-627)NLM012629065 |x 1879-1166 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:28 |g month:03 |g pages:110794 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.humimm.2024.110794 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 28 |c 03 |h 110794 | ||